Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Rating of “Moderate Buy” by Brokerages

Charles River Laboratories International, Inc. (NYSE:CRL) has been given an average rating of “Moderate Buy” by the sixteen ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $203.5714.

A number of equities research analysts have weighed in on the company. Bank of America upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price for the company in a research report on Monday, December 15th. TD Cowen lowered their price target on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Citigroup upped their price objective on Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a report on Friday, January 16th. UBS Group raised their target price on Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Finally, Wall Street Zen lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st.

More Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Zacks raised its FY2027 EPS view to $11.62 (from $11.30), signaling stronger full‑year outlook and supporting a higher valuation multiple. Zacks FY2027 boost
• Positive Sentiment: Zacks lifted FY2026 EPS to $10.78 (from $10.68), implying near‑term margin or revenue improvement versus prior assumptions. Zacks FY2026 boost
• Positive Sentiment: Zacks published FY2028 EPS of $12.12, reflecting continued expected earnings growth beyond FY2027. Long‑term upgrades can lift investor sentiment. Zacks FY2028 outlook
• Positive Sentiment: Multiple quarterly raises: Q3 2026 to $2.86, Q3 2027 to $3.02, Q4 2026 to $3.02, and Q4 2027 to $3.32 — these sequential upgrades point to improving quarterly momentum. Zacks quarterly upgrades
• Positive Sentiment: Zacks raised mid‑2026 quarterly views (Q2 2026 to $2.85 and Q2/Q3 2026 lifts), indicating expectations for recovery or stronger demand in the upcoming fiscal periods. Zacks mid‑2026 raises
• Neutral Sentiment: Zacks’ estimates differ from the consensus full‑year figure repeatedly cited ($9.36), meaning analyst views remain divergent; the Zacks upgrades imply upside versus consensus but do not change consensus itself. Consensus vs Zacks
• Negative Sentiment: Zacks lowered Q1 2026 EPS from $2.39 to $2.05, a material near‑term cut that could pressure the next quarter’s reported results and short‑term sentiment. Zacks Q1 2026 cut
• Negative Sentiment: Zacks slightly trimmed Q2 2027 to $2.65 (from $2.67), a minor downgrade but another signal of some variability in near‑term cadence. Zacks Q2 2027 trim

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $155.61 on Friday. The stock has a market cap of $7.66 billion, a P/E ratio of -52.57, a P/E/G ratio of 2.61 and a beta of 1.64. The firm’s 50-day simple moving average is $191.59 and its 200 day simple moving average is $180.88. Charles River Laboratories International has a fifty-two week low of $91.86 and a fifty-two week high of $228.88. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.33 by $0.06. The firm had revenue of $994.23 million for the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. Charles River Laboratories International’s quarterly revenue was down .8% on a year-over-year basis. During the same quarter last year, the company earned $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Equities analysts expect that Charles River Laboratories International will post 9.36 EPS for the current year.

Institutional Trading of Charles River Laboratories International

A number of hedge funds and other institutional investors have recently made changes to their positions in CRL. Cardinal Capital Management lifted its stake in Charles River Laboratories International by 0.6% during the fourth quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock valued at $2,180,000 after buying an additional 62 shares in the last quarter. Asset Management One Co. Ltd. increased its stake in shares of Charles River Laboratories International by 4.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock worth $375,000 after acquiring an additional 71 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Charles River Laboratories International by 11.2% during the third quarter. Hantz Financial Services Inc. now owns 793 shares of the medical research company’s stock worth $124,000 after acquiring an additional 80 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in shares of Charles River Laboratories International by 1.3% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock worth $1,260,000 after acquiring an additional 80 shares in the last quarter. Finally, Advisory Services Network LLC boosted its position in Charles River Laboratories International by 2.6% during the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock valued at $505,000 after purchasing an additional 83 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.